{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:42:40Z","timestamp":1770745360552,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s40256-020-00411-3","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T09:05:56Z","timestamp":1591607156000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks"],"prefix":"10.1007","volume":"21","author":[{"given":"Tim","family":"Hollstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Kassner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Grenkowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friederike","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bobbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Steinhagen-Thiessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"issue":"29","key":"411_CR1","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315\u201381. https:\/\/doi.org\/10.1093\/eurheartj\/ehw106.","journal-title":"Eur Heart J"},{"issue":"14","key":"411_CR2","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","volume":"39","author":"U Landmesser","year":"2018","unstructured":"Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Boren J, et al. 2017 Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018;39(14):1131\u201343. https:\/\/doi.org\/10.1093\/eurheartj\/ehx549.","journal-title":"Eur Heart J"},{"issue":"1","key":"411_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"411_CR4","unstructured":"Amgen Inc. Repatha prescribing information. 2015. https:\/\/pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/repatha\/repatha_pi_hcp_english.ashx. Accessed 31 May 2020."},{"key":"411_CR5","unstructured":"Amgen Europe B.V. Repatha summary of product characteristics. 2019. https:\/\/www.medicines.org.uk\/emc\/medicine\/30628. Accessed 31 May 2020."},{"key":"411_CR6","unstructured":"Sanofi-Aventis U.S. LLC. Praluent summary of product characteristics. 2015. https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003882\/WC500194521.pdf. Accessed  31 May 2020."},{"key":"411_CR7","unstructured":"Sanofi. Praluent Prescribing Information. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125559Orig1s000lbledt.pdf. Accessed 31 May 2020."},{"key":"411_CR8","unstructured":"Sanofi. Statement Regarding D\u00fcsseldorf Regional Court Decision in Ongoing Praluent\u00ae (alirocumab) Patent Litigation in Germany. 2019. https:\/\/www.sanofi.com\/en\/media-room\/press-statements\/statement-regarding-dusseldorf-regional-court-decision-in-ongoing-praluent-alirocumab-patent-litigation-in-germany. Accessed 31 May 2020."},{"key":"411_CR9","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.ijcard.2016.08.273","volume":"223","author":"M Farnier","year":"2016","unstructured":"Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY phase 3 clinical program trials. Int J Cardiol. 2016;223:750\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2016.08.273.","journal-title":"Int J Cardiol"},{"issue":"33","key":"411_CR10","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","volume":"35","author":"EA Stein","year":"2014","unstructured":"Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014;35(33):2249\u201359. https:\/\/doi.org\/10.1093\/eurheartj\/ehu085.","journal-title":"Eur Heart J"},{"issue":"22","key":"411_CR11","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"18","key":"411_CR12","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"key":"411_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2017.11.027","volume":"270","author":"RM Stoekenbroek","year":"2018","unstructured":"Stoekenbroek RM, Hartgers ML, Rutte R, de Wijer DD, Stroes ESG, Hovingh GK. PCSK9 inhibitors in clinical practice: delivering on the promise? Atherosclerosis. 2018;270:205\u201310. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.11.027.","journal-title":"Atherosclerosis"},{"issue":"8","key":"411_CR14","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cjca.2018.04.014","volume":"34","author":"O Razek","year":"2018","unstructured":"Razek O, Cermakova L, Armani H, Lee T, Francis GA, Mancini GBJ, et al. Attainment of recommended lipid targets in patients with familial hypercholesterolemia: real-world experience with PCSK9 inhibitors. Can J Cardiol. 2018;34(8):1004\u20139. https:\/\/doi.org\/10.1016\/j.cjca.2018.04.014.","journal-title":"Can J Cardiol"},{"issue":"5","key":"411_CR15","doi-asserted-by":"publisher","first-page":"e12439","DOI":"10.1111\/1755-5922.12439","volume":"36","author":"B Zafrir","year":"2018","unstructured":"Zafrir B, Jubran A. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: two-year experience of a regional lipid clinic. Cardiovasc Ther. 2018;36(5):e12439. https:\/\/doi.org\/10.1111\/1755-5922.12439.","journal-title":"Cardiovasc Ther"},{"issue":"1","key":"411_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5603\/CJ.a2017.0137","volume":"25","author":"M Saborowski","year":"2018","unstructured":"Saborowski M, Dolle M, Manns MP, Leitolf H, Zender S. Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: effectiveness, therapy adherence and safety in a real world cohort. Cardiol J. 2018;25(1):32\u201341. https:\/\/doi.org\/10.5603\/CJ.a2017.0137.","journal-title":"Cardiol J"},{"issue":"3","key":"411_CR17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jacl.2017.02.014","volume":"11","author":"AMH Galema-Boers","year":"2017","unstructured":"Galema-Boers AMH, Lenzen MJ, Sijbrands EJ, Roeters van Lennep JE. Proprotein convertase subtilisin\/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience. J Clin Lipidol. 2017;11(3):674\u201381. https:\/\/doi.org\/10.1016\/j.jacl.2017.02.014.","journal-title":"J Clin Lipidol."},{"issue":"11","key":"411_CR18","doi-asserted-by":"publisher","first-page":"e13032","DOI":"10.1111\/ijcp.13032","volume":"71","author":"M Kohli","year":"2017","unstructured":"Kohli M, Patel K, MacMahon Z, Ramachandran R, Crook MA, Reynolds TM, et al. Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. Int J Clin Pract. 2017;71(11):e13032. https:\/\/doi.org\/10.1111\/ijcp.13032.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"411_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40261-019-00877-3","volume":"40","author":"C Piccinni","year":"2020","unstructured":"Piccinni C, Antonazzo IC, Maggioni AP, Pedrini A, Calabria S, Ronconi G, et al. PCSK9 inhibitors' new users: analysis of prescription patterns and patients' characteristics from an Italian real-world study. Clin Drug Investig. 2020;40(2):173\u201381. https:\/\/doi.org\/10.1007\/s40261-019-00877-3.","journal-title":"Clin Drug Investig"},{"key":"411_CR20","unstructured":"Charit\u00e9 Universit\u00e4tsmedizin Berlin. Die Behandlung der therapierefrakt\u00e4ren Hypercholesterin\u00e4mie mit proprotein convertase subtilisin\/kexin type 9 (PCSK9)-Antik\u00f6rpern bei Hochrisikopatienten \u2013 Effektivit\u00e4t und Vertr\u00e4glichkeit im klinischen Alltag. 2016. https:\/\/www.pei.de\/SharedDocs\/awb\/nis-0301-0400\/0342.html. Accessed 31 May 2020."},{"issue":"17","key":"411_CR21","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012\u201322. https:\/\/doi.org\/10.1093\/eurheartj\/ehv043.","journal-title":"Aetiol Manag Eur Heart J"},{"issue":"44","key":"411_CR22","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3238\/arztebl.2015.0748","volume":"112","author":"U Laufs","year":"2015","unstructured":"Laufs U, Scharnagl H, Halle M, Windler E, Endres M, M\u00e4rz W. Treatment options for statin-associated muscle symptoms. Deutsches Arzteblatt Int. 2015;112(44):748\u201355. https:\/\/doi.org\/10.3238\/arztebl.2015.0748.","journal-title":"Deutsches Arzteblatt Int"},{"issue":"25 Suppl 2","key":"411_CR23","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1\u201345. https:\/\/doi.org\/10.1161\/01.cir.0000437738.63853.7a.","journal-title":"Circulation"},{"issue":"1","key":"411_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.atherosclerosis.2015.03.003","volume":"240","author":"K Haralambos","year":"2015","unstructured":"Haralambos K, Whatley SD, Edwards R, Gingell R, Townsend D, Ashfield-Watt P, et al. Clinical experience of scoring criteria for familial hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis. 2015;240(1):190\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.03.003.","journal-title":"Atherosclerosis"},{"issue":"23","key":"411_CR25","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531\u201340. https:\/\/doi.org\/10.1016\/j.jacc.2014.03.018.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"411_CR26","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jacl.2018.01.013","volume":"12","author":"CJ Glueck","year":"2018","unstructured":"Glueck CJ, Brown A, Goldberg AC, McKenney JM, Kantaros L, Stewart J, et al. Alirocumab in high-risk patients: observations from the open-label expanded use program. J Clin Lipidol. 2018;12(3):662\u20138. https:\/\/doi.org\/10.1016\/j.jacl.2018.01.013.","journal-title":"J Clin Lipidol"},{"key":"411_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319888059","author":"F Sbrana","year":"2019","unstructured":"Sbrana F, Pino BD, Bigazzi F, Ripoli A, Volpi E, Fogliaro MP, et al. A large Italian cohort on proprotein convertase subtilisin\/kexin type 9 inhibitors. Eur J Prevent Cardiol. 2019. https:\/\/doi.org\/10.1177\/2047487319888059.","journal-title":"Eur J Prevent Cardiol"},{"issue":"10","key":"411_CR28","doi-asserted-by":"publisher","first-page":"e005367","DOI":"10.1161\/jaha.116.005367","volume":"6","author":"PP Toth","year":"2017","unstructured":"Toth PP, Worthy G, Gandra SR, Sattar N, Bray S, Cheng LI, et al. Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia. J Am Heart Assoc. 2017;6(10):e005367.https:\/\/doi.org\/10.1161\/jaha.116.005367.","journal-title":"J Am Heart Assoc."},{"issue":"6","key":"411_CR29","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","volume":"8","author":"PM Moriarty","year":"2014","unstructured":"Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccara-Dinet MT, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8(6):554\u201361. https:\/\/doi.org\/10.1016\/j.jacl.2014.09.007.","journal-title":"J Clin Lipidol"},{"key":"411_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2018.08.036","volume":"278","author":"M Farnier","year":"2018","unstructured":"Farnier M, Hovingh GK, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, et al. Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: an open-label extension of the ODYSSEY program. Atherosclerosis. 2018;278:307\u201314. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.08.036.","journal-title":"Atherosclerosis"},{"issue":"22","key":"411_CR31","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1161\/circulationaha.117.027705","volume":"135","author":"JW Knowles","year":"2017","unstructured":"Knowles JW, Howard WB, Karayan L, Baum SJ, Wilemon KA, Ballantyne CM, et al. Access to nonstatin lipid-lowering therapies in patients at high risk of atherosclerotic cardiovascular disease. Circulation. 2017;135(22):2204\u20136. https:\/\/doi.org\/10.1161\/circulationaha.117.027705.","journal-title":"Circulation"},{"issue":"3","key":"411_CR32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40265-018-0867-9","volume":"78","author":"TF Whayne","year":"2018","unstructured":"Whayne TF. Outcomes, access, and cost issues involving PCSK9 inhibitors to lower LDL-cholesterol. Drugs. 2018;78(3):287\u201391. https:\/\/doi.org\/10.1007\/s40265-018-0867-9.","journal-title":"Drugs"},{"key":"411_CR33","unstructured":"Gemeinsamer Bundesausschuss. Alirocumab. 2019. https:\/\/www.g-ba.de\/downloads\/91-1385-407\/2019-05-02_Geltende-Fassung_Alirocumab_D-194_D-409.pdf. Accessed 31 May 2020"},{"key":"411_CR34","unstructured":"Gemeinsamer Bundesausschuss. Evolocumab. 2018. https:\/\/www.g-ba.de\/downloads\/91-1385-354\/2018-09-06_Geltende-Fassung_Evolocumab_D-345.pdf. Accessed 31 May 2020"},{"issue":"5","key":"411_CR35","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacl.2018.06.002","volume":"12","author":"T Sampietro","year":"2018","unstructured":"Sampietro T, Bigazzi F, Sbrana F, Toma M, Dal Pino B, Ripoli A, et al. Personalized regimen for PCSK9 inhibitors: a therapeutic option that maintains efficacy and reduces costs. J Clin Lipidol. 2018;12(5):1324\u20135. https:\/\/doi.org\/10.1016\/j.jacl.2018.06.002.","journal-title":"J Clin Lipidol"},{"key":"411_CR36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-511x-7-22","volume":"7","author":"J Mayne","year":"2008","unstructured":"Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Disease. 2008;7:22. https:\/\/doi.org\/10.1186\/1476-511x-7-22.","journal-title":"Lipids Health Disease"},{"issue":"4","key":"411_CR37","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1074\/jbc.M708098200","volume":"283","author":"S Poirier","year":"2008","unstructured":"Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283(4):2363\u201372. https:\/\/doi.org\/10.1074\/jbc.M708098200.","journal-title":"J Biol Chem"},{"issue":"3","key":"411_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40801-019-0158-0","volume":"6","author":"KG Parhofer","year":"2019","unstructured":"Parhofer KG, von Stritzky B, Pietschmann N, Dorn C, Paar WD. PEARL: a non-interventional study of real-world alirocumab use in German clinical practice. Drugs Real World Outcomes. 2019;6(3):115\u201323. https:\/\/doi.org\/10.1007\/s40801-019-0158-0.","journal-title":"Drugs Real World Outcomes"},{"issue":"6","key":"411_CR39","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758\u201369. https:\/\/doi.org\/10.1016\/j.jacl.2015.08.006.","journal-title":"J Clin Lipidol"},{"issue":"23","key":"411_CR40","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2014.03.019.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"411_CR41","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.amjcard.2016.08.072","volume":"118","author":"PH Jones","year":"2016","unstructured":"Jones PH, Bays HE, Chaudhari U, Pordy R, Lorenzato C, Miller K, et al. Safety of alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials. Am J Cardiol. 2016;118(12):1805\u201311. https:\/\/doi.org\/10.1016\/j.amjcard.2016.08.072.","journal-title":"Am J Cardiol"},{"issue":"40","key":"411_CR42","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/eurheartj\/ehv161","volume":"36","author":"GM Rosano","year":"2015","unstructured":"Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H, et al. Gender differences in the effect of cardiovascular drugs: a position document of the working group on pharmacology and drug therapy of the ESC. Eur Heart J. 2015;36(40):2677\u201380. https:\/\/doi.org\/10.1093\/eurheartj\/ehv161.","journal-title":"Eur Heart J"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00411-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-020-00411-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00411-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T23:47:48Z","timestamp":1623109668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-020-00411-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["411"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00411-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"8 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Tim Hollstein received non-financial support from Sanofi during the conduct of the study and has received non-financial support from Sanofi and Amgen unrelated to the submitted work. Ursula Kassner has received speaker honoraria from Amgen, Sanofi, Alexion, Amrhyt, Berlin Chemie, Fresenius Medical Care, and Synlab Academy. Thomas Grenkowitz has received personal fees from Sanofi and Fresenius Medical Care unrelated to the submitted work. Friederike Schumann has received grants from Amgen unrelated to the submitted work. Thomas Bobbert has no potential conflicts of interest that might be relevant to this work. Elisabeth Steinhagen-Thiessen has received speakers\u2019 honoraria from Sanofi, Amgen, Pfizer, Berlin Chemie, and Akcea.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}